{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:47:49Z","timestamp":1793407669845,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014425","name":"Acorda Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.parkreldis.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T12:55:41Z","timestamp":1589201741000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Clinical implications of gastric complications on levodopa treatment in Parkinson's disease"],"prefix":"10.1016","volume":"76","author":[{"given":"Ronald F.","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"14","author":"Fasano","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib2","first-page":"6762528","article-title":"Gastrointestinal dysfunctions in Parkinson's disease: symptoms and treatments","author":"Poirier","year":"2016","journal-title":"Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib4","series-title":"Does Parkinson's Begin in the Gut?","author":"Kwon","year":"2018"},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11940-018-0539-9","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"20","author":"Pfeiffer","year":"2018","journal-title":"Curr. Treat. Options Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.05.001_bib6","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/gps.5100","article-title":"Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies","volume":"34","author":"Durcan","year":"2019","journal-title":"Int. J. Geriatr. Psychiatr."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.870060211","article-title":"Gastrointestinal symptoms in Parkinson's disease","volume":"6","author":"Edwards","year":"1991","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.clineuro.2012.07.032","article-title":"Prevalence of non motor features in a cohort of Parkinson's disease patients","volume":"115","author":"Khedr","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","article-title":"Association of autonomic dysfunction with disease progression and survival in Parkinson disease","volume":"74","author":"De Pablo-Fernandez","year":"2017","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/JPD-2011-001","article-title":"Gastrointestinal disorders in Parkinson's disease: prevalence and health outcomes in a US claims database","volume":"1","author":"Makaroff","year":"2011","journal-title":"J. Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(12)70049-2","article-title":"Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation","volume":"11","author":"Fasano","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2047-9158-4-1","article-title":"Meta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis","volume":"4","author":"Chen","year":"2015","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.57.3.456","article-title":"Frequency of bowel movements and the future risk of Parkinson's disease","volume":"57","author":"Abbott","year":"2001","journal-title":"Neurology"},{"issue":"Suppl 7","key":"10.1016\/j.parkreldis.2020.05.001_bib14","article-title":"Life style risks of Parkinson's disease: association between decreased water intake and constipation","volume":"251","author":"Ueki","year":"2004","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.parkreldis.2020.05.001_bib15","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/mds.22705","article-title":"Major nutritional issues in the management of Parkinson's disease","volume":"24","author":"Barichella","year":"2009","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053290","article-title":"Malnutrition in a sample of community-dwelling people with Parkinson's disease","volume":"8","author":"Sheard","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease,","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov. Disorder"},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","article-title":"Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial","volume":"35","author":"Pintor","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12883-015-0362-9","article-title":"Rate of aspiration pneumonia in hospitalized Parkinson's disease patients: a cross-sectional study","volume":"15","author":"Martinez-Ramirez","year":"2015","journal-title":"BMC Neurol."},{"issue":"Suppl 11","key":"10.1016\/j.parkreldis.2020.05.001_bib20","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib21","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","article-title":"Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease","volume":"63","author":"Hauser","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2015.11.007","article-title":"Risk and course of motor complications in a population-based incident Parkinson's disease cohort","volume":"22","author":"Bjornestad","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mds.25708","article-title":"Delayed gastric emptying in Parkinson's disease","volume":"29","author":"Marrinan","year":"2014","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.parkreldis.2011.12.004","article-title":"Gastroparesis and Parkinson's disease: a systematic review","volume":"18","author":"Heetun","year":"2012","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.parkreldis.2018.02.021","article-title":"A wrinkle in ON-time - a GI structural abnormality confounding levodopa therapy with Duodopa rescue; a case study","volume":"50","author":"Staisch","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.neuro.2018.02.013","article-title":"Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson's disease","volume":"65","author":"Johnson","year":"2018","journal-title":"Neurotoxicology"},{"issue":"10","key":"10.1016\/j.parkreldis.2020.05.001_bib28","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s11064-018-2620-x","article-title":"Intestinal pathology and gut microbiota alterations in a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease","volume":"43","author":"Lai","year":"2018","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2019.07.006","article-title":"The structure and function of the human small intestinal microbiota: current understanding and future directions","volume":"9","author":"Kastl","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.4.2.193","article-title":"Irregular gastrointestinal drug absorption in Parkinson\u2019s disease","volume":"4","author":"Nyholm","year":"2008","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mds.1203","article-title":"Gastric emptying time and gastric motility in patients with Parkinson's disease","volume":"16","author":"Hardoff","year":"2001","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib32","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/mds.25522","article-title":"The role of small intestinal bacterial overgrowth in Parkinson's disease","volume":"28","author":"Fasano","year":"2013","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis","volume":"108","author":"Camilleri","year":"2013","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/0016-5085(84)90079-9","article-title":"Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease","volume":"87","author":"Qualman","year":"1984","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00687767","article-title":"Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses","volume":"76","author":"Wakabayashi","year":"1988","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","article-title":"Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen","volume":"110","author":"Braak","year":"2003","journal-title":"J. Neural. Transm."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","article-title":"Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology","volume":"396","author":"Braak","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fneur.2017.00037","article-title":"Exploring Braak's hypothesis of Parkinson's disease","volume":"8","author":"Rietdijk","year":"2017","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1749-6632.2009.04365.x","article-title":"Parkinson's disease: the dual hit theory revisited","volume":"1170","author":"Hawkes","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.05.001_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113573","article-title":"What is the evidence that Parkinson's disease is a prion disorder, which originates in the gut?","volume":"19","author":"Kujawska","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.25298","article-title":"Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease","volume":"28","author":"Gold","year":"2013","journal-title":"Mov. Disord."},{"issue":"s1","key":"10.1016\/j.parkreldis.2020.05.001_bib43","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3233\/JPD-181477","article-title":"The gut and Parkinson's disease: hype or hope?","volume":"8","author":"Scheperjans","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"2015","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2982.2006.00780.x","article-title":"Predictors of gastric emptying in Parkinson\u2019s disease","volume":"18","author":"Goetze","year":"2006","journal-title":"Neurogastroenterol. Motil."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5056\/jnm.2010.16.1.99","article-title":"The incidence, prevalence, and survival of gastroparesis in Olmsted County, Minnesota, 1996-2006 (Gastroenterology 2009;136:1225-1233","volume":"16","author":"Jung","year":"2010","journal-title":"J. Neurogastroenterol. Motil"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/ajg.2011.310","article-title":"Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population","volume":"107","author":"Choung","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-019-0087-3","article-title":"Gastric dysmotility in Parkinson's disease is not caused by alterations of the gastric pacemaker cells","volume":"5","author":"Heimrich","year":"2019","journal-title":"NPJ. Parkinsons Dis."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2017-000132","article-title":"Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson's disease who present with functional gastrointestinal symptoms","volume":"4","author":"Su","year":"2017","journal-title":"BMJ Open Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2020.05.001_bib51","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1093\/ageing\/afu047.4","article-title":"On behalf of the ProBand clinical consortium, Gastroparesis symptoms in early Parkinson's disease [Abstract 131 BGS]","volume":"43","author":"Marrinan","year":"2014","journal-title":"Age Ageing"},{"issue":"19","key":"10.1016\/j.parkreldis.2020.05.001_bib52","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1212\/WNL.0b013e318236ef60","article-title":"Parkinson disease: the enteric nervous system spills its guts","volume":"77","author":"Derkinderen","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5056\/jnm18162","article-title":"Gastroparesis and functional dyspepsia: a blurring distinction of pathophysiology and treatment","volume":"25","author":"Kim","year":"2019","journal-title":"J. Neurogastroenterol. Motil"},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0016-5085(77)80073-5","article-title":"Gastric emptying of solid food in normal man and after subtotal gastrectomy and truncal vagotomy with pyloroplasty","volume":"72","author":"MacGregor","year":"1977","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gtc.2014.11.003","article-title":"Clinical presentation and pathophysiology of gastroparesis","volume":"44","author":"Nguyen","year":"2015","journal-title":"Gastroenterol. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/RLU.0000000000001470","article-title":"Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses","volume":"42","author":"Bestetti","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.1980.55","article-title":"Interaction of levodopa and metoclopramide on gastric emptying","volume":"27","author":"Berkowitz","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib58","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/gut.45.3.346","article-title":"Cholinergic effects on human gastric motility","volume":"45","author":"Parkman","year":"1999","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib59","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00003643-199904000-00006","article-title":"Dopamine delays gastric emptying and prolongs orocaecal transit time in volunteers","volume":"16","author":"Levein","year":"1999","journal-title":"Eur. J. Anaesthesiol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib60","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00280127","article-title":"The influence of levodopa on gastric emptying in healthy elderly volunteers","volume":"42","author":"Robertson","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"6445","key":"10.1016\/j.parkreldis.2020.05.001_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6323","article-title":"Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism","volume":"364","author":"Maini Rekdal","year":"2019","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neulet.2004.11.007","article-title":"Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test","volume":"375","author":"Goetze","year":"2005","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2967\/jnmt.107.048116","article-title":"Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine","volume":"36","author":"Abell","year":"2008","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.parkreldis.2018.06.003","article-title":"Gastric emptying in Parkinson\u2019s disease - a mini-review","volume":"55","author":"Knudsen","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00415-005-0815-y","article-title":"Gastric emptying after semi-solid food in multiple system atrophy and Parkinson disease","volume":"252","author":"Thomaides","year":"2005","journal-title":"J. Neurol."},{"issue":"25","key":"10.1016\/j.parkreldis.2020.05.001_bib66","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.3748\/wjg.v22.i25.5742","article-title":"Gut dysfunction in Parkinson's disease","volume":"22","author":"Mukherjee","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib67","first-page":"795","article-title":"A technical review and clinical assessment of the wireless motility capsule","volume":"7","author":"Saad","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib68","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11894-016-0489-x","article-title":"The wireless motility capsule: a one-stop shop for the evaluation of GI motility disorders","volume":"18","author":"Saad","year":"2016","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/2050640613510161","article-title":"Gastrointestinal motility revisited: the wireless motility capsule","volume":"1","author":"Farmer","year":"2013","journal-title":"United Eur. Gastroenterol. J."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00002826-200603000-00001","article-title":"Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients","volume":"29","author":"Muller","year":"2006","journal-title":"Clin. Neuropharmacol."},{"issue":"360","key":"10.1016\/j.parkreldis.2020.05.001_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8858","article-title":"Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease","volume":"8","author":"Lipp","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib72","unstructured":"Safirstein B., Ellenbogen A., Zhao P., Henney H. III, Kegler-Ebo D., Oh C., Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson's disease, Clin. Therapeut. (In press)."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib73","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.46.4.1051","article-title":"Gastric emptying in Parkinson's disease: patients with and without response fluctuations","volume":"46","author":"Djaldetti","year":"1996","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2020.05.001_bib74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","article-title":"Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease","volume":"319","author":"Doi","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib75","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","year":"2002","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib76","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1007\/s00415-009-5220-5","article-title":"Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test","volume":"256","author":"Tanaka","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4236\/apd.2017.61001","article-title":"Is levodopa pharmacokinetics in patients with Parkinson's disease depending on gastric emptying?","volume":"6","author":"Nord","year":"2017","journal-title":"Adv. Parkinson's Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3233\/JPD-181327","article-title":"Stomaching the possibility of a pathogenic role for Helicobacter pylori in Parkinson's disease","volume":"8","author":"McGee","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"40","key":"10.1016\/j.parkreldis.2020.05.001_bib79","doi-asserted-by":"crossref","first-page":"11221","DOI":"10.3748\/wjg.v21.i40.11221","article-title":"Diagnosis of Helicobacter pylori infection: current options and developments","volume":"21","author":"Wang","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib80","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1046\/j.1365-2036.2000.00815.x","article-title":"Parkinsonism: differential age-trend in Helicobacter pylori antibody","volume":"14","author":"Dobbs","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib81","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12398","article-title":"Meta-analysis: association of Helicobacter pylori infection with Parkinson's diseases","volume":"22","author":"Shen","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.parkreldis.2017.11.331","article-title":"Helicobacter pylori infection is associated with an increased risk of Parkinson's disease: a population-based retrospective cohort study","volume":"47","author":"Huang","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib83","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1468-1331.2011.03643.x","article-title":"Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark","volume":"19","author":"Nielsen","year":"2012","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.parkreldis.2014.12.009","article-title":"Helicobacter pylori infection is associated with worse severity of Parkinson's disease","volume":"21","author":"Tan","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clineuro.2018.09.039","article-title":"H. pylori and Parkinson's disease: meta-analyses including clinical severity","volume":"175","author":"Dardiotis","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib86","first-page":"CD008453","article-title":"Helicobacter pylori eradication for Parkinson's disease","volume":"11","author":"Rees","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib87","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1007\/s00415-013-7089-6","article-title":"Motor fluctuations and Helicobacter pylori in Parkinson's disease","volume":"260","author":"Rahne","year":"2013","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib88","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/hel.12035","article-title":"Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity","volume":"18","author":"Dobbs","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clineuro.2017.07.003","article-title":"Eradication of Helicobacter pylori infection might improve clinical status of patients with Parkinson's disease, especially on bradykinesia","volume":"160","author":"Liu","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.05.001_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112330","article-title":"Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease","volume":"9","author":"Hashim","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib91","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.1267","article-title":"Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients","volume":"50","author":"Pierantozzi","year":"2001","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3988\/jcn.2017.13.2.181","article-title":"Association of Helicobacter pylori with Parkinson's disease","volume":"13","author":"Mridula","year":"2017","journal-title":"J. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/WNF.0000000000000037","article-title":"Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection","volume":"37","author":"Narozanska","year":"2014","journal-title":"Clin. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib94","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","article-title":"Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations","volume":"66","author":"Pierantozzi","year":"2006","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.parkreldis.2020.05.001_bib95","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1517\/14656566.2015.1086747","article-title":"The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson\u2019s disease","volume":"16","author":"Barboza","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib96","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/gut.2005.078121","article-title":"Treatment options for patients with severe gastroparesis","volume":"56","author":"Abrahamsson","year":"2007","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.parkreldis.2020.05.001_bib97","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-016-0386-8","article-title":"Novel levodopa formulations for Parkinson's disease","volume":"30","author":"Freitas","year":"2016","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.parkreldis.2020.05.001_bib98","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s11095-017-2162-y","article-title":"Continuous transdermal delivery of L-DOPA based on a self-assembling nanomicellar system","volume":"34","author":"Sintov","year":"2017","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"10","key":"10.1016\/j.parkreldis.2020.05.001_bib99","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/10837450.2016.1245319","article-title":"Enhancement of levodopa stability when complexed with beta-cyclodextrin in transdermal patches","volume":"23","author":"Obaidat","year":"2018","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"16","key":"10.1016\/j.parkreldis.2020.05.001_bib100","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.parkreldis.2020.05.001_bib101","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","article-title":"Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study","volume":"20","author":"Rizos","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib102","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/mdc3.12350","article-title":"Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease","volume":"4","author":"Isaacson","year":"2017","journal-title":"Mov. Disord Clin. Pract."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib103","series-title":"APO-go Pen 10mg\/ml Solution for Injection. Summary of Product Characteristics","year":"2018"},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib104","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol."},{"issue":"S1","key":"10.1016\/j.parkreldis.2020.05.001_bib105","first-page":"S162","article-title":"Constant therapeutic levodopa (LD) plasma concentrations maintained by continuous subcutaneous (SC) administration of ND-0612, a novel formulation of LD\/carbidopa (CD)","volume":"28","author":"Caraco","year":"2013","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.05.001_bib106","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","article-title":"Levodopa in Parkinson's disease: current status and future developments","volume":"16","author":"Tambasco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib107","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P3.8-037","article-title":"A novel levodopa\/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson's disease (P3.8-037)","volume":"92","author":"Rosebraugh","year":"2019","journal-title":"Neurology"},{"issue":"15 Supplement","key":"10.1016\/j.parkreldis.2020.05.001_bib108","article-title":"A novel levodopa\/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson\u2019s disease (P3.8-037)","volume":"92","author":"Rosebraugh","year":"2019","journal-title":"Neurology"},{"issue":"16 Supplement","key":"10.1016\/j.parkreldis.2020.05.001_bib109","article-title":"Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: results from the Phase 3 study dose-titration phase (P1.017)","volume":"88","author":"Hauser","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib110","author":"Lopes"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib111","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/npjparkd.2016.23","article-title":"Non-oral dopaminergic therapies for Parkinson\u2019s disease: current treatments and the future","volume":"2","author":"Chaudhuri","year":"2016","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib112","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fneur.2018.00620","article-title":"Levodopa-carbidopa intestinal gel in Parkinson's disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib113","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","article-title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"18","author":"LeWitt","year":"2019","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib114","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/mds.26611","article-title":"A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease","volume":"31","author":"LeWitt","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib115","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/NDT.S147633","article-title":"Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date","volume":"14","author":"Patel","year":"2018","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib116","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/jamp.2016.1354","article-title":"Pulmonary safety and tolerability of inhaled levodopa (CVT-301) administered to patients with Parkinson's disease","volume":"31","author":"LeWitt","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.parkreldis.2019.12.012","article-title":"Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study","volume":"71","author":"Grosset","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib118","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mds.27340","article-title":"Medical and surgical management of advanced Parkinson's disease","volume":"33","author":"Antonini","year":"2018","journal-title":"Mov. Disord."},{"issue":"Pt 5","key":"10.1016\/j.parkreldis.2020.05.001_bib119","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/brain\/aws086","article-title":"Subthalamic deep brain stimulation can improve gastric emptying in Parkinson's disease","volume":"135","author":"Arai","year":"2012","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.5009\/gnl16336","article-title":"Gastroparesis updates on pathogenesis and management","volume":"11","author":"Liu","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib121","series-title":"REGLAN\u00ae (Metoclopramide) Tablets, for Oral Use. Prescribing Information","year":"2017"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib122","first-page":"976","article-title":"The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis","volume":"92","author":"Soykan","year":"1997","journal-title":"Am. J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib123","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1365-2125.1984.tb02571.x","article-title":"Domperidone and levodopa in Parkinson's disease","volume":"18","author":"Shindler","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib124","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00002826-198610000-00004","article-title":"Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease","volume":"9","author":"Langdon","year":"1986","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.05.001_bib125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/WNF.0b013e3182575cdb","article-title":"Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease","volume":"35","author":"Nishikawa","year":"2012","journal-title":"Clin. Neuropharmacol."},{"issue":"1416","key":"10.1016\/j.parkreldis.2020.05.001_bib126","first-page":"66","article-title":"Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations","volume":"128","author":"Buffery","year":"2015","journal-title":"N. Z. Med. J."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib127","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5056\/jnm15094","article-title":"Prokinetics in the management of functional gastrointestinal disorders","volume":"21","author":"Quigley","year":"2015","journal-title":"J. Neurogastroenterol. Motil"},{"issue":"8","key":"10.1016\/j.parkreldis.2020.05.001_bib128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.parkreldis.2005.06.007","article-title":"Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease","volume":"11","author":"Asai","year":"2005","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib129","first-page":"1","article-title":"The effect of prucalopride on gastric emptying in Parkinson's disease patients, a pilot randomized, open-label study","volume":"1","author":"Pinyopornpanish","year":"2017","journal-title":"Digestive Syst."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib130","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/gut.2004.060426","article-title":"Influence of ghrelin on interdigestive gastrointestinal motility in humans","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.parkreldis.2020.05.001_bib131","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2005-2638","article-title":"Ghrelin stimulates gastric emptying and hunger in normal-weight humans","volume":"91","author":"Levin","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.05.001_bib132","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gut.2005.069088","article-title":"Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study","volume":"54","author":"Murray","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.05.001_bib133","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2337\/dc12-1128","article-title":"Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics","volume":"36","author":"Shin","year":"2013","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.parkreldis.2020.05.001_bib134","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1365-2036.2009.03986.x","article-title":"Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis","volume":"29","author":"Ejskjaer","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.05.001_bib135","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1111\/j.1365-2982.2012.01904.x","article-title":"Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats","volume":"24","author":"Wang","year":"2012","journal-title":"Neurogastroenterol. Motil."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.05.001_bib136","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \"on-off\" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport","volume":"310","author":"Nutt","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40734-016-0036-9","article-title":"Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease","volume":"3","author":"Virmani","year":"2016","journal-title":"J. Clin. Mov. Disord"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib138","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1038\/npjsba.2016.13","article-title":"Model-based dietary optimization for late-stage, levodopa-treated, Parkinson's disease patients","volume":"2","author":"Guebila","year":"2016","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.parkreldis.2020.05.001_bib139","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fnagi.2017.00206","article-title":"Protein-restricted diets for ameliorating motor fluctuations in Parkinson's disease","volume":"9","author":"Wang","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.05.001_bib140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","article-title":"Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients","volume":"10","author":"Baruzzi","year":"1987","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib141","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000116649","article-title":"Protein redistribution diet and antiparkinsonian response to levodopa","volume":"31","author":"Bracco","year":"1991","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib142","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archneur.1987.00520150026014","article-title":"Influence of dietary protein on motor fluctuations in Parkinson's disease","volume":"44","author":"Pincus","year":"1987","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.05.001_bib143","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archneur.1992.00530260049018","article-title":"Protein redistribution diet remains effective in patients with fluctuating parkinsonism","volume":"49","author":"Karstaedt","year":"1992","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.05.001_bib144","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/WNL.38.3.481","article-title":"Protein redistribution diet restores motor function in patients with dopa-resistant \"off\" periods","volume":"38","author":"Pincus","year":"1988","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.parkreldis.2020.05.001_bib145","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1212\/WNL.38.7.1026","article-title":"Practical application of a low-protein diet for Parkinson's disease","volume":"38","author":"Riley","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2020.05.001_bib146","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.06.020","article-title":"Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease","volume":"56","author":"Tan","year":"2018","journal-title":"Park. Relat. Disord."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020301103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:13:49Z","timestamp":1762370029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020301103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":146,"alternative-id":["S1353802020301103"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.001","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of gastric complications on levodopa treatment in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}